PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.81%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
36.41%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
439.57%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
440.81%
EPS growth above 1.5x GNPX's 34.62%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
440.81%
Diluted EPS growth above 1.5x GNPX's 34.62%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
681.03%
OCF growth above 1.5x GNPX's 7.14%. David Dodd would confirm a clear edge in underlying cash generation.
681.03%
FCF growth above 1.5x GNPX's 7.14%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1209.68%
10Y OCF/share CAGR above 1.5x GNPX's 91.62%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
1209.68%
5Y OCF/share CAGR above 1.5x GNPX's 96.48%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
1209.68%
3Y OCF/share CAGR above 1.5x GNPX's 96.26%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
934.70%
Net income/share CAGR above 1.5x GNPX's 99.56% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
934.70%
5Y net income/share CAGR above 1.5x GNPX's 96.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
934.70%
3Y net income/share CAGR above 1.5x GNPX's 96.48%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-244.00%
Negative equity/share CAGR over 10 years while GNPX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-244.00%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-244.00%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2826.88%
Positive asset growth while GNPX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
26.94%
Positive BV/share change while GNPX is negative. John Neff sees a clear edge over a competitor losing equity.
3.22%
Debt growth of 3.22% while GNPX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-10.82%
We cut SG&A while GNPX invests at 52.68%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.